The analysis printed within the Journal of An infection investigated using metagenomic next-generation sequencing (mNGS) in diagnosing bloodstream infections (BSIs) for immunocompromised hematology sufferers. Hematology sufferers are extremely vulnerable to BSIs, which may have extreme penalties similar to septic shock, multiple-organ failure, disseminated intravascular coagulation, and even dying. An correct and fast microbiological analysis of BSI is subsequently important for the management of the an infection.
Traits of 256 immunocompromised sufferers with suspected bloodstream infections view extra
Picture Credit score: BGI Genomics
Within the research carried out between January 2019 and December 2020 at Tongji Hospital with the participation of BGI Genomics researcher Wenqian Zhang, peripheral blood samples had been collected from 256 immunocompromised hematology sufferers suspected of BSI, and each mNGS and traditional microbiological checks (CMTs) had been carried out . BSI analysis was confirmed in 189 out of 256 sufferers (73.8%). The detection charge of mNGS was considerably larger than that of CMTs, with mNGS figuring out 187 an infection instances and CMTs figuring out 81. Outcomes point out mNGS outperformed CMT in detecting bloodstream infections.
Micro organism had been detected in 17 sufferers (6.6%), fungi in 15 sufferers (5.9%), uncommon pathogens in 4 sufferers (1.6%), and a number of species in 55 sufferers (21.5%).
Primarily based on mNGS outcomes, viral an infection was essentially the most frequent BSI, recognized in 96 out of 256 sufferers (37.5%). The 5 most typical causative viruses had been CMV (31.3%), EBV (14.8%), HSV1 (11.7%), BK virus (11.7%) and HHV6B (9.4%).
The outcomes additionally confirmed that it was extra seemingly for sufferers who had undergone hematopoietic stem cell transplantation (HSCT), than those that had not, to be contaminated by BK virus and HHV6B.
Total, the research highlights the potential of mNGS as a strong software for the fast and correct analysis of BSIs in immunocompromised hematology sufferers, permitting for well timed and efficient therapy.
About BGI Genomics
BGI Genomics, headquartered in Shenzhen China, is the world’s main built-in options supplier of precision drugs. Our companies cowl over 100 international locations and areas, involving greater than 2,300 medical establishments. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was formally listed on the Shenzhen Inventory Trade.
